These injectable obesity treatments, although different in their specific approaches, share a common goal: to significantly improve the quality of life of patients. Mounjaro and Wegovy, initially developed for diabetes, have shown promising results in managing obesity, while Saxenda, directly targeting obesity, helps regulate appetite effectively. Each of these drugs illustrates the progress of medical technologies and opens up new opportunities for patients looking to regain control of their health in a safe clinical setting.
The Mounjaro
The Mounjaro stands out as an improved version of its predecessor, the Zepbound. Designed specifically for people with diabetes, this innovative treatment uses tirzepatide to optimize blood glucose levels, contributing to better blood sugar balance.
Transformative Impacts: Promising Weight Loss Results
Clinical trials provide a glimmer of hope with results that exceed expectations: an average weight loss of 22 kg is observed after 72 weeks of treatment. Data suggests that up to 18% reduction in body mass is possible, opening the door to significant long-term health benefits.
Progress and prospects: towards accessibility in France
Although Mounjaro is not yet available on the French market, the authorisation procedures are underway, and the establishment of a production plant in Alsace is planned. This step is crucial to make treatment accessible to a greater number of patients in need.
Precautions and Administration
The treatment comes in the form of an injection, available in six different dosages to best suit individual needs. However, it should be noted that the most common side effects include gastrointestinal upset, such as nausea, vomiting, and constipation.
Wegovy
Since 2021, the Wegovy treatment has made its appearance in the United States, providing a new option for those struggling with obesity. This drug has demonstrated significant effectiveness, allowing patients to lose between 5 and 20% of their weight in a year. Some testimonials, such as that of a patient who lost more than 30 kg in just one year, illustrate the potentially transformative results of this treatment.
Origin and Mechanism of Action
Initially designed for the treatment of diabetes, the Wegovy, produced by the Danish laboratory Novo Nordisk, was adapted for obesity after extensive tests on more than 7,000 patients. Its active ingredient, semaglutide, acts as a hormone that regulates the feeling of satiety, tricking the brain into thinking it has received enough carbohydrates.
Precautions and Administration
Despite its benefits, Wegovy, like any “appetite suppressant” drug, is not without risks. Side effects, including digestive upset such as nausea and vomiting, require special attention. Doctors emphasize the importance of correct use to maximize the benefits of the treatment. Wegovy Weight Loss Injection is administered weekly, with a recommended protocol of at least 16 weeks to see significant results.
Saxenda
In the fight against obesity and overweight, Saxenda presents itself as a promising therapeutic option. This injection treatment is particularly recommended for patients with comorbidity factors. Based on liraglutide, Saxenda acts effectively on appetite and the feeling of satiety by mimicking the action of GLP-1, a natural hormone that also regulates blood sugar levels after meals.
Clinically proven results and effectiveness
Clinical trials involving nearly 6,000 participants reveal impressive results: an average loss of 7.2 kg over a 20-week period. In addition, about three-quarters of the patients treated managed to lose more than 5% of their initial weight, while 28% decreased their weight by more than 10%.
Administration and precautions
To minimize the risk of side effects, including gastrointestinal disorders such as nausea, diarrhea, vomiting, and constipation, Saxenda treatment is given gradually in five doses. This gradual approach allows the body to adapt to the medication and to optimize theTo improve results while maintaining maximum patient comfort.
Saxenda is therefore an effective and safe solution, offering people affected by obesity a real path to better health and an improved quality of life.
